![Five-Star Basketball Prospect Severely Injured In Fiery Tesla Cybertruck Crash [Update]](https://www.jalopnik.com/img/gallery/five-star-basketball-prospect-severely-injured-in-fiery-tesla-cybertruck-crash/l-intro-1745597808.jpg?#)
Fierce Pharma Asia—Enhertu's first-line win; Akeso bispecific's positive readout; Regeneron, Fujifilm's $3B deal
AstraZeneca and Daiichi Sankyo are gunning to get oncology med Enhertu a first-line approval in HER2-positive breast cancer after a positive phase 3 readout. Akeso's bispecific ivonescimab has bagged another phase 3 win in first-line lung cancer. Fujifilm Diosynth signed a 10-year manufacturing contract with Regeneron.
AstraZeneca and Daiichi Sankyo are gunning to get oncology med Enhertu a first-line approval in HER2-positive breast cancer after a positive phase 3 readout. Akeso's bispecific ivonescimab has bagged another phase 3 win in first-line lung cancer. Fujifilm Diosynth signed a 10-year manufacturing contract with Regeneron.
